The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) on September 13, 2016. This approval, categorized as an efficacy supplement (BLA 125554 S-17), signifies the agency's acceptance of new data supporting the drug's effectiveness.
Background
Nivolumab, marketed as Opdivo, is developed by Bristol Myers Squibb. Supplemental applications are a common regulatory mechanism for drug sponsors to update or expand a drug's approved uses. An efficacy supplement specifically pertains to new clinical data that demonstrates the drug's effectiveness, potentially for a new indication, a new patient population, or an updated dosing regimen for an already approved use.
What this means
This supplemental approval for Opdivo (nivolumab) for efficacy means that the FDA has officially recognized additional evidence demonstrating the drug's effectiveness. While the specific details of the indication or patient population are not provided in this record, such approvals typically expand the utility or confirm the benefit of a drug in a new context. This provides clinicians with more options for patient care and reinforces the drug's profile as an effective treatment, reflecting an update to the drug's approved label based on new clinical findings.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for biologics license application (BLA) 125554 S-17, concerning Opdivo (nivolumab), was recorded on September 13, 2016, on accessdata.fda.gov.